These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

618 related items for PubMed ID: 23866594

  • 1. [New markers of cardio-renal links in chronic kidney disease].
    Milovanova LIu, Milovanov IuS, Kozlovskaia LV, Mukhin NA.
    Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
    [Abstract] [Full Text] [Related]

  • 2. [Significance of the morphogenetic proteins FGF-23 and Klotho as predictors of prognosis of chronic kidney disease].
    Milovanova LIu, Milovanov IuS, Kozlovskaia LV, Mukhin NA.
    Ter Arkh; 2014; 86(4):36-44. PubMed ID: 24864466
    [Abstract] [Full Text] [Related]

  • 3. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY, Milovanov YS, Kudryavtseva DV, Markina MM, Milovanova SY, Kozlovskaya LV, Lebedeva MV, Beketov VD, Moiseev SV, Mukhin NA, Fomin VV, Svistunov AA.
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [Abstract] [Full Text] [Related]

  • 4. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
    Milovanova LY, Kozlovskaya LV, Markina MM, Milovanova SY, Borisov AA, Mukhin NA, Fomin VV, Moiseev SV.
    Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
    [Abstract] [Full Text] [Related]

  • 5. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
    Milovanov YS, Mukhin NA, Kozlovskaya LV, Milovanova SY, Markina MM.
    Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257
    [Abstract] [Full Text] [Related]

  • 6. Serum klotho: relation to fibroblast growth factor-23 and other regulators of phosphate metabolism in children with chronic kidney disease.
    Sawires HK, Essam RM, Morgan MF, Mahmoud RA.
    Nephron; 2015; 129(4):293-9. PubMed ID: 25766835
    [Abstract] [Full Text] [Related]

  • 7. [The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease].
    Mukhin NA, Milovanov YS, Kozlovskaya LV, Dobrosmyslov IA, Milovanova LY.
    Ter Arkh; 2016; 88(4):41-45. PubMed ID: 27070162
    [Abstract] [Full Text] [Related]

  • 8. [Anemia of chronic diseases in the early stages of chronic kidney disease as a risk factor for cardiovascular complications in patients with glomerulonephritis].
    Markina MV, Milovanova LY, Lysenko LV, Milovanova SY, Volkov AV, Beketov VD, Lebedeva MV, Nezhdanov KS, Moiseev SV.
    Ter Arkh; 2024 Jul 07; 96(6):606-613. PubMed ID: 39106502
    [Abstract] [Full Text] [Related]

  • 9. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
    Lima F, Mawad H, El-Husseini AA, Davenport DL, Malluche HH.
    Clin Nephrol; 2019 Apr 07; 91(4):222-230. PubMed ID: 30862350
    [Abstract] [Full Text] [Related]

  • 10. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y, Olauson H, Vavilis G, Hammar U, Herthelius M, Axelsson J, Bárány P.
    Pediatr Nephrol; 2018 Jan 07; 33(1):147-157. PubMed ID: 28795324
    [Abstract] [Full Text] [Related]

  • 11. Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration.
    Milovanova LY, Dobrosmyslov IA, Milovanov YS, Taranova MV, Kozlov VV, Milovanova SY, Kozevnikova EI.
    Ter Arkh; 2018 Jun 20; 90(6):48-54. PubMed ID: 30701904
    [Abstract] [Full Text] [Related]

  • 12. Correlation of serum levels of fibroblast growth factor 23 and Klotho protein levels with bone mineral density in maintenance hemodialysis patients.
    Zheng S, Chen Y, Zheng Y, Zhou Z, Li Z.
    Eur J Med Res; 2018 Apr 17; 23(1):18. PubMed ID: 29665846
    [Abstract] [Full Text] [Related]

  • 13. Plasmatic Klotho and FGF23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients.
    Silva AP, Mendes F, Carias E, Gonçalves RB, Fragoso A, Dias C, Tavares N, Café HM, Santos N, Rato F, Leão Neves P, Almeida E.
    Int J Mol Sci; 2019 Mar 27; 20(7):. PubMed ID: 30934737
    [Abstract] [Full Text] [Related]

  • 14. [Osteoprotegerin and fibroblast growth factor 23 in the development of cardiovascular events in chronic kidney disease].
    Dzgoeva FU, Gatagonova TM, Bestaeva TL, Sopoev MIu, Bazaeva BG, Khamitsaeva OV.
    Ter Arkh; 2014 Mar 27; 86(6):63-9. PubMed ID: 25095658
    [Abstract] [Full Text] [Related]

  • 15. [Fibroblast growth factor 23 and a novel high-sensitivity troponin I: Early markers and alternative ways of damaging the heart in chronic kidney disease].
    Dzgoeva FU, Sopoev MY, Gatagonova TM, Bestaeva TL, Khamitsaeva OV.
    Ter Arkh; 2015 Mar 27; 87(6):68-74. PubMed ID: 26281199
    [Abstract] [Full Text] [Related]

  • 16. Soluble α-klotho and its relation to kidney function and fibroblast growth factor-23.
    Scholze A, Liu Y, Pedersen L, Xia S, Roth HJ, Hocher B, Rasmussen LM, Tepel M.
    J Clin Endocrinol Metab; 2014 May 27; 99(5):E855-61. PubMed ID: 24606097
    [Abstract] [Full Text] [Related]

  • 17. Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b-4 stages chronic кidney disease patients: a randomized pilot study.
    Milovanova L, Fomin V, Moiseev S, Taranova M, Milovanov Y, Lysenko Kozlovskaya L, Kozlov V, Kozevnikova E, Milovanova S, Lebedeva M, Reshetnikov V.
    Clin Exp Nephrol; 2018 Dec 27; 22(6):1351-1359. PubMed ID: 29948444
    [Abstract] [Full Text] [Related]

  • 18. Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation.
    Eser B, Yayar O, Buyukbakkal M, Erdogan B, Ercan Z, Merhametsiz O, Haspulat A, Oğuz EG, Dogan İ, Canbakan B, Ayli MD.
    Nefrologia; 2015 Dec 27; 35(5):465-72. PubMed ID: 26394828
    [Abstract] [Full Text] [Related]

  • 19. [Correlations of FGF23 and Klotho with cardiovascular injury in chronic kidney disease patients].
    Gan L, Zhou Q.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Sep 28; 42(9):1058-1065. PubMed ID: 28989152
    [Abstract] [Full Text] [Related]

  • 20. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.
    Manou E, Thodis E, Arsos G, Pasadakis P, Panagoutsos S, Papadopoulou D, Papagianni A.
    Kidney Blood Press Res; 2020 Sep 28; 45(6):900-915. PubMed ID: 33040068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.